Defunct Company
Total Trials
11
As Lead Sponsor
0
As Collaborator
Total Enrollment
571
NCT02324621
Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors
Phase: Phase 1
Role: Collaborator
Start: Feb 20, 2015
Completion: Oct 23, 2018
NCT02392572
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Phase: Phase 1/2
Start: Nov 3, 2015
Completion: Nov 30, 2026
NCT02525692
Oral ONC201 in Adult Recurrent Glioblastoma
Phase: Phase 2
Start: Jan 31, 2016
Completion: Apr 17, 2023
NCT02863991
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
Start: Apr 19, 2017
Completion: Dec 16, 2019
NCT03099499
Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer
Start: Jun 8, 2017
Completion: Sep 9, 2020
NCT03295396
ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
Start: Oct 30, 2017
Completion: Jul 19, 2023
NCT03416530
ONC201 in Pediatric H3 K27M Gliomas
Start: Jan 25, 2018
Completion: May 24, 2023
NCT03485729
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
Start: Mar 21, 2018
Completion: Jan 19, 2023
NCT03791398
BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC
Start: Nov 15, 2019
Completion: Aug 5, 2021
NCT04854044
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma
Start: May 1, 2021
Completion: Jul 1, 2026
NCT05542407
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
Start: Oct 23, 2023
Completion: Jul 31, 2026